Drug Trial Radar · NCT07223411
Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Nov 19, 2025
Primary completion
Nov 1, 2028
Study completion Nov 1, 2031
Sponsor
- Lead sponsor
- John KirkwoodAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Oct 31, 2025
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
Summary
As written by the sponsor on the registry.
This translational study will examine the immune effector responses of patients who received a two-drug combination for first line therapy by examining tumor and peripheral blood of participants with unresectable locally advanced or metastatic melanoma.
Conditions
- Locally Advanced Melanoma
Interventions
Fianlimab + CemiplimabDrug
Patients treated with Fianlimab 1600 mg + Cemiplimab 350 mg under protocol NCT06246916
Relatlimab + NivolumabDrug
Patients treated with Relatlimab 160 mg + Nivolumab 480 mg under protocol NCT06246916
Primary outcomes
What the sponsor says the trial is designed to measure.
- Single-cell analysis of CD4+ T cellsTime frame: Up to 39 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.